Radost Vatcheva
Overview
Explore the profile of Radost Vatcheva including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
1288
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brough R, Bajrami I, Vatcheva R, Natrajan R, Reis-Filho J, Lord C, et al.
EMBO J
. 2012 Feb;
31(5):1160-76.
PMID: 22293751
Mutations in BRCA2 confer an increased risk of cancer development, at least in part because the BRCA2 protein is required for the maintenance of genomic integrity. Here, we use proteomic...
2.
Lambros M, Wilkerson P, Natrajan R, Patani N, Pawar V, Vatcheva R, et al.
Lab Invest
. 2011 Aug;
91(10):1491-501.
PMID: 21808235
Fusion genes have pivotal roles in the development and progression of human cancer and offer potential for rational drug design. Massively parallel sequencing has identified a panoply of in-frame expressed...
3.
Tan D, Iravani M, McCluggage W, Lambros M, Milanezi F, Mackay A, et al.
Clin Cancer Res
. 2011 Mar;
17(6):1521-34.
PMID: 21411445
Purpose: Ovarian clear cell carcinomas (OCCC) are a drug-resistant and aggressive type of epithelial ovarian cancer. We analyzed the molecular genetic profiles of OCCCs to determine whether distinct genomic subgroups...
4.
Dedes K, Wetterskog D, Mendes-Pereira A, Natrajan R, Lambros M, Geyer F, et al.
Sci Transl Med
. 2010 Oct;
2(53):53ra75.
PMID: 20944090
PTEN (phosphatase and tensin homolog) loss of function is the most common genetic aberration in endometrioid endometrial carcinomas. In addition to its well-described role in cell signaling, PTEN is involved...
5.
Dedes K, Lopez-Garcia M, Geyer F, Lambros M, Savage K, Vatcheva R, et al.
Breast Cancer Res Treat
. 2010 Mar;
124(3):653-66.
PMID: 20213079
Amplification of 11q13 is found in approximately 15% of breast cancers. Cyclin D1 (CCND1) has been reported to be the 'driver' of this amplicon, however, multiple genes map to the...
6.
Geyer F, Weigelt B, Natrajan R, Lambros M, de Biase D, Vatcheva R, et al.
J Pathol
. 2010 Jan;
220(5):562-73.
PMID: 20099298
Cancers may be composed of multiple populations of submodal clones sharing the same initiating genetic lesions, followed by the acquisition of divergent genetic hits. Intra-tumour genetic heterogeneity has profound implications...
7.
Natrajan R, Weigelt B, Mackay A, Geyer F, Grigoriadis A, Tan D, et al.
Breast Cancer Res Treat
. 2009 Aug;
121(3):575-89.
PMID: 19688261
Breast cancer is a heterogeneous disease caused by the accumulation of genetic changes in neoplastic cells. We hypothesised that molecular subtypes of breast cancer may be driven by specific constellations...
8.
Klingbeil P, Natrajan R, Everitt G, Vatcheva R, Marchio C, Palacios J, et al.
Breast Cancer Res Treat
. 2009 Apr;
120(1):95-109.
PMID: 19350388
Overexpression and alternative splicing of CD44 have been implicated in tumour progression. Here we describe the identification of a high level amplification of human 11p13, encompassing the CD44 gene, in...
9.
Natrajan R, Lambros M, Rodriguez-Pinilla S, Moreno-Bueno G, Tan D, Marchio C, et al.
Clin Cancer Res
. 2009 Mar;
15(8):2711-22.
PMID: 19318498
Purpose: To characterize the molecular genetic profiles of grade 3 invasive ductal carcinomas of no special type using high-resolution microarray-based comparative genomic hybridization (aCGH) and to identify recurrent amplicons harboring...
10.
Tan D, Lambros M, Rayter S, Natrajan R, Vatcheva R, Gao Q, et al.
Clin Cancer Res
. 2009 Mar;
15(7):2269-80.
PMID: 19293255
Purpose: To identify therapeutic targets in ovarian clear cell carcinomas, a chemoresistant and aggressive type of ovarian cancer. Experimental Design: Twelve ovarian clear cell carcinoma cell lines were subjected to...